L-type fatty acid binding protein (L-FABP) detection kit

L-type fatty acid binding protein (L-FABP) detection kit

Can be used for animal model experiments of chronic kidney disease and acute kidney injury, drug-induced nephrotoxicity experiments, and evaluation of candidate drugs with potential renal protective functions!

This product is an ELISA kit that uses sandwich method to quantify L-FABP (L-type Fatty Acid Binding Protein) in urine.

The correlation between L-FABP and microcirculatory disorders (ischemia), sepsis, drug-induced kidney damage, and other evaluation experimental results can be viewedManufacturer's website: https://fabp.jp/eng/

◆What is L-FABP?

L-FABP is a fatty acid binding protein that is locally present in the cytoplasm of human renal proximal tubular cells, with a molecular weight of 14-15 kDa. L-FABP in the cytoplasm binds to free fatty acids and promotes beta oxidation by transporting them to mitochondria and peroxisomes, helping to maintain energy generation and homeostasis of the internal environment.Due to ischemia/reperfusion injury around the renal tubules, reactive oxygen species can convert free fatty acids into highly cytotoxic peroxidized lipids. L-FABP is believed to protect the kidneys by binding to these peroxidized lipids and excreting them from cells, as shown in the red box below.

Before the tissue damage expands, L-FABP is excreted from the urine due to tubular ischemia or oxidative stress. Therefore, it can be used to evaluate early 'renal diseases with tubular dysfunction'.

◆Detection Principle

After treating standard L-FABP or urine samples with pre-treatment solution, add reaction buffer to the pre dispensed anti-L-FABP antibody solid-phase well plate. After cleaning the well plate, add enzyme labeled antibodies as secondary antibodies. Wash after reaction, add substrate solution for enzyme reaction, and measure absorbance.

All reagents are ready to use, saving preparation time and suppressing adjustment errors.

◆characteristic

The L-FABP detection kit produced by CMIC company has rich human clinical data support

●The product series includes different types of L-FABP detection kits for rats, monkeys, humans, etc

●Seamless evaluation from non clinical to clinical samples can be achieved

◆Testing achievements

Urine L-FABP in the field of human diabetes

Test object: 147 patients with diabetes nephropathy

Detection method: For the above cases, the average and standard deviation were calculated in stages according to different disease stages, and the L-FABP of healthy individuals was also displayed.

● The L-FABP value of patients with diabetes nephropathy increases with the development of the disease.

Since the value of L-FABP in the early stage of nephropathy is significantly higher than that of healthy people, detection of L-FABP is helpful for the early diagnosis of diabetes nephropathy.

Test object: 104 patients with type 2 diabetes

Detection method: A 4-year follow-up investigation was conducted on the above-mentioned cases.

The progression of kidney disease: an increase in urinary albumin levels, progression to advanced renal failure, and introduction of hemodialysis.

Even in the albuminuria stage, patients with high urinary L-FABP values have a risk of developing kidney disease that is about 7 times higher than other patients.

It can simultaneously monitor L-FABP, which reflects renal tubular function, and urinary albumin, which is a marker of glomerular injury, and predict renal function deterioration with high accuracy.

◆Usage example

2Detection of urinary L-FABP in type 2 diabetes model rats and SDT fat rats

Experimental animals: Male SDT fat rats *, Male SD rats (control group)

Experimental steps: Collect urine samples from SDT fat rats and SD rats at 8 weeks, 16 weeks, and 24 weeks of age, and detect urine L-FABP and creatinine.

(CMIC data)

<Use reagent kit>

Rat L-FABP ELISA Kit (Part Number :008, CMIC HOLDINGS Co., Ltd.)

QuantiChrom Creatinine Assay Kit (DICT-500 ,BioAssay Systems)

Test results: When renal tubular lesions were confirmed, the urinary L-FABP value increased at 8 weeks of age.

*About SDT Fatty Rats

Spontaneous type 2 diabetes model rats produced and sold by CLEA Japan, Inc.

Because it has the characteristics of specific glomerular nodular lesions of human diabetes nephropathy, it is considered to be used for the pathological analysis of CKD and the development of therapeutic drugs. Additionally, the condition of the model rats can be controlled through experiments. For example, reducing glomerular filtration rate (GFR) before and after 18 weeks of age through unilateral nephrectomy and physiological saline load. It has been confirmed that renal tubular lesions can be observed at around 8 weeks of age (Exp. Anim. 57 (2), 111-121, 2008).

◆ Product List